LENSAR, Inc.

LNSR

NASDAQ

Healthcare

Medical - Devices

Orlando, FL, US140 employeeslensar.com

$6.01

+0.04(0.67%)

Mkt Cap $72M

$5.52

$14.18

52-Week Range

At a Glance

AI-generated

LENSAR delivered $58.4M revenue amid growth strategy execution, but operating loss of $24.6M and net loss of $34.3M reflect merger disruptions, tariff-driven cost pressures, and fleet expansion investments.

Revenue breakdown: Product (89.1%), Service (10.9%).

8-K

LENSAR reported Q4 2025 total revenue of $16.0 million, down 4% year-over-year, with recurring revenue up 17% to $12.7 million representing 79% of total, alongside ALLY system placements of 15 units.

$72M

Market Cap

$59M

Revenue

-$51M

Net Income

Employees140

Fundamentals

How The Business Makes Money

Revenue by Segment

Product89.1%($87M)

Service10.9%($11M)

Revenue by Geography

US64.8%($63M)

Europe19%($19M)

Asia Excluding South Korea13.8%($14M)

KR1.5%($2M)

Other Geographical Region0.8%($801.0K)

Activity

What Changed Recently

Financial Results

Mar 30, 2026

Results of Operations and Financial Condition. On March 31, 2026, LENSAR, Inc. (the “Company”) issued a press release announcing financial results for the fisca

Other Event

Mar 12, 2026

Other Events. On March 12, 2026, LENSAR, Inc. (the “Company”) reported that it has entered into a Priority Credit Line Agreement, dated as of March 11, 2026 (th

Other Event

Mar 11, 2026

Other Events. On March 12, 2026, LENSAR, Inc. (the “Company”) reported that it has entered into a Priority Credit Line Agreement, dated as of March 11, 2026 (th

Regulation FD

Feb 24, 2026

and in Exhibit 99.1 of this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Excha

Peer Companies

Company	Price	Change	Market Cap	P/E
ANIKAnika Therapeutics, Inc.	$14.81	-1.13%	$214M	-18.7
AVRAnteris Technologies Glob...	$5.50	+3.29%	$202M	-1.4
PROFProfound Medical Corp.	$6.39	-2.14%	$193M	-3.6
TLSITriSalus Life Sciences, I...	$4.22	+1.08%	$160M	-4.7
CRBPCorbus Pharmaceuticals Ho...	$10.29	+3.11%	$129M	-1.4
CRDFCardiff Oncology, Inc.	$1.58	-1.86%	$108M	-2.6
RPIDRapid Micro Biosystems, I...	$2.27	+4.86%	$103M	-2.2
OWLTOwlet, Inc.	$5.12	+0.49%	$93M	-78.3

Analyst View

Company Profile

CIK0001320350

ISINUS52634L1089

CUSIP52634L108

Phone888 536 7271

Address2800 Discovery Drive, Orlando, FL, 32826, US

SEC EDGAR